Optimization and Individualization of Diagnostic Scintigraphy Protocol and Minimally Invasive Radio-guided Parathyroid Surgery
Primary Hyperparathyroidism, Thyroid Disease, Parathyroid Diseases
About this trial
This is an interventional treatment trial for Primary Hyperparathyroidism focused on measuring minimally-invasive radio-guided parathyroidectomy, in-vivo, ex-vivo, multi-phase SPECT/CT, individualized treatment
Eligibility Criteria
Inclusion Criteria:
- Adult patients
- No history of thyroid or parathyroid surgery
- Diagnosis of primary hyperparathyroidism
- Indication for 99mTc-MIBI SPECT/CT examination
Exclusion Criteria:
- Minor patients
- Negative SPECT/CT findings
- Patients refusing surgery
- Previous combined surgery on the thyroid gland
- Patients in high risk of general anesthesia
- Patients who do not undergo surgery in the recommended time span
Sites / Locations
- University Hospital Ostrava
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Conventional (dual-phase) SPECT/CT
Multi-phase SPECT/CT
Adult patients with primary hyperparathyroidism undergoing conventional (dual-phase) SPECT/CT (after 10 and 150 minutes) and conventional minimally-invasive radio-guided parathyroidectomy in a time span 2-3 hours from radionuclide administration.
Adult patients with primary hyperparathyroidism undergoing multi-phase SPECT/CT (after 10, 90, 150, 210 minutes) and individualized minimally-invasive radio-guided parathyroidectomy performed in a recommended time span based on standardized uptake value calculation.